Clinical Trials
Braintumor Website

There are 49 trials:
Facility: Massachusetts General Hospital
NCT Trial Name# of Centers

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT02573324

  A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
185

NCT00085735

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
184

NCT02667587

  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
121

NCT02320058

  An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
35

NCT02052778

  A Study of TAS-120 in Patients With Advanced Solid Tumors
28

NCT02997423

  Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
19

NCT02632370

  5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
14

NCT03150862

  A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma
12

NCT01967810

  ANG1005 in Patients With Recurrent High-Grade Glioma
11

NCT02844439

  Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
10

NCT01790503

  A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
9

NCT02337491

  Pembrolizumab +/- Bevacizumab for Recurrent GBM
8

NCT02586857

  A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
7

NCT01339052

  Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
7

NCT02977780

  INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
7

NCT02981940

  A Study of Abemaciclib in Recurrent Glioblastoma
7

NCT02852655

  A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
6

NCT00859222

  LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
5

NCT01112527

  PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
4

NCT03215511

  Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
4

NCT02968940

  Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
4

NCT03071874

  Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
3

NCT00916630

  Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
3

NCT01063114

  Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
2

NCT01182415

  High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
2

NCT01466036

  Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
2

NCT01331291

  Bosutinib in Adult Patients With Recurrent Glioblastoma
2

NCT00821080

  Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
2

NCT01921335

  ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
2

NCT02693990

  A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
2

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
2

NCT02525692

  Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma
2

NCT02142803

  TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
2

NCT02260531

  Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
2

NCT03139916

  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
2

NCT03279692

  Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
2

NCT03286335

  Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
1

NCT02843230

  Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
1

NCT03281889

  Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
1

NCT02076152

  FMISO PET Study of Glioblastoma
1

NCT01867593

  MET-PET for Newly Diagnosed Glioblastoma
1

NCT02831257

  AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
1

NCT02896335

  Palbociclib In Progressive Brain Metastases
1

NCT01846871

  Tivozanib for Recurrent Glioblastoma
1

NCT01228448

  In-Room PET in Proton Radiation Therapy
1

NCT01288235

  Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
1

NCT01358058

  Proton Radiation Therapy for Gliomas
1

NCT01115777

  Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites